Fennec Pharmaceuticals (TSE:FRX) Insider Sells C$1,799,524.00 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) insider Southpoint Capital Advisors Lp sold 160,100 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of C$11.24, for a total transaction of C$1,799,524.00. Following the sale, the insider owned 3,850,000 shares of the company’s stock, valued at C$43,274,000. This trade represents a 3.99% decrease in their position.

Southpoint Capital Advisors Lp also recently made the following trade(s):

• On Monday, November 17th, Southpoint Capital Advisors Lp sold 85,918 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$12.35, for a total transaction of C$1,061,087.30.
• On Tuesday, October 7th, Southpoint Capital Advisors Lp sold 26,900 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$13.23, for a total transaction of C$355,887.00.
• On Wednesday, October 8th, Southpoint Capital Advisors Lp sold 19,605 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$13.07, for a total transaction of C$256,237.35.
• On Thursday, October 9th, Southpoint Capital Advisors Lp sold 20,609 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$12.89, for a total value of C$265,650.01.

Fennec Pharmaceuticals Price Performance

Fennec Pharmaceuticals stock remained flat at C$10.60 during trading on Friday. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company’s 50 day moving average is C$11.61 and its 200 day moving average is C$11.72. Fennec Pharmaceuticals Inc. has a twelve month low of C$7.02 and a twelve month high of C$13.83. The company has a market cap of C$362.02 million, a price-to-earnings ratio of -40.77 and a beta of 2.51.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.